News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GeneData (USA), Inc. Releases Patent Analysis Software Jointly Developed with DSM


7/28/2010 12:20:51 PM

Basel, Switzerland - July 28, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced the release of PatentExplorer, an interdisciplinary software tool for assessing the patent situation of novel biomolecules and targets. Part of the Genedata Phylosopher® biological data management system, PatentExplorer integrates patent information to provide a comprehensive and structured analysis of patented biomolecule sequences, related claim information, and freedom-to-operate. This facilitates intellectual property evaluation from both a business and a biological standpoint. PatentExplorer was developed in close collaboration with DSM, a leading global life science company with major research programs in enzymes, nutrition, and biotechnology, to streamline DSM's global R&D activities.

"Today's industrial biotechnology market is driven by innovation. Securing the intellectual property of life science research at DSM is crucial in order to retain a competitive advantage," explained Dr. Wim de Boer, Intellectual Assets Manager at DSM. "We chose Genedata to help us develop an integrated platform to manage our project intellectual property information because Genedata has significant scientific, technical and business experience and this has been a key factor in the success of this joint development project."

"PatentExplorer integrates directly into DSM's global genome sequence information management system, which is based on the Genedata Phylosopher software platform," said Dr. Hans Roubos, Senior Scientist Bioinformatics at DSM. "It provides direct access to the most recent patent information in the context of DSM's in-house genomics research data, which gives much appreciated transparency to decision making."

PatentExplorer's primary applications are in the development of novel enzymes and engineered proteins, as well as freedom-to-operate assessment support. The software can handle commercial data sources as well as publicly available patent information. Genedata's proprietary GeneIndex technology is pivotal for the automated and systematic integration of the often disparate and duplicated DNA, RNA and protein patent sequences.

"We are excited about our successful collaboration with DSM, a long-term partner of Genedata and one of the most innovative leaders in the industrial biotechnology sector," noted Dr. Othmar Pfannes, CEO of Genedata. "With the addition of the PatentExplorer module to our well-established Genedata Phylosopher system, we have addressed a major need for biotechnology and biologics research projects. We now offer PatentExplorer to a wider market to facilitate comprehensive and timely investigation of intellectual property across complex R&D programs in the life sciences and pharmaceutical industry."

About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan and the US. www.genedata.com

Contacts Allison Kurz Genedata Marketing & Communications Phone: +41 61 511 8459 communications@genedata.com

Jackie Thrasivoulos Genedata Public Relations Phone: +1 508 881 3109 jackie.thrasivoulos@genedata.com

Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES